Protalix BioTherapeutics, Inc.
PLXAMEXHealthcare● Active
$1.96
$-0.03(-1.51%)
Market Cap$157920418
P/E Ratio—
52W High$3.19
52W Low$1.32
Protalix BioTherapeutics, Inc. (PLX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PLX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
$0.22
Est. -$0.01 · +2300.0%
Revenue
$0.03B
Est. $0.01B · +193.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
PLX reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.01 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.01 | $0.22 | +2300.0% | $0.03B | $0.01B | +193.5% |
| ▼ Q1 FY2026 | Mar 18, 2026 | $0.01 | -$0.07 | -800.0% | $0.01B | $0.02B | -50.1% |
| ▼ Q4 FY2025 | Nov 13, 2025 | $0.06 | $0.03 | -50.0% | $0.02B | $0.01B | +25.3% |
| ▼ Q3 FY2025 | Aug 14, 2025 | $0.03 | $0.00 | -93.3% | $0.02B | $0.01B | +16.1% |
| ▼ Q2 FY2025 | May 9, 2025 | $0.08 | -$0.05 | -162.5% | $0.01B | $0.02B | -56.2% |
| ▲ Q1 FY2025 | Mar 17, 2025 | $0.07 | $0.09 | +28.6% | $0.02B | $0.02B | -15.7% |
| ▼ Q4 FY2024 | Nov 14, 2024 | $0.06 | $0.03 | -50.0% | $0.02B | $0.02B | -1.4% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
$0.22
EPS Est.
-$0.01
EPS Surpr.
+2300.0%
Revenue
$0.03B
Q1 FY2026
Mar 18, 2026Miss
EPS Actual
-$0.07
EPS Est.
$0.01
EPS Surpr.
-800.0%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
$0.03
EPS Est.
$0.06
EPS Surpr.
-50.0%
Revenue
$0.02B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
$0.00
EPS Est.
$0.03
EPS Surpr.
-93.3%
Revenue
$0.02B
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.05
EPS Est.
$0.08
EPS Surpr.
-162.5%
Revenue
$0.01B
Q1 FY2025
Mar 17, 2025Beat
EPS Actual
$0.09
EPS Est.
$0.07
EPS Surpr.
+28.6%
Revenue
$0.02B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
$0.03
EPS Est.
$0.06
EPS Surpr.
-50.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
| Q3 FY2027 | $0.03 | $0.03 | $0.03 | 1 |
| Q2 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
| Q1 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
| Q4 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2026 | $-0.03 | $-0.01 | $0.01 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +2300.0% | $1.91 | $1.93 | +1.05% |
| ▼ Q1 FY2026 | Mar 18, 2026 | -800.0% | $2.79 | $2.21 | -20.79% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -50.0% | $2.14 | $1.93 | -9.81% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -93.3% | $1.61 | $1.52 | -5.59% |
| ▼ Q2 FY2025 | May 9, 2025 | -162.5% | $2.89 | $1.72 | -40.48% |
| ▲ Q1 FY2025 | Mar 17, 2025 | +28.6% | $2.24 | $2.45 | +9.37% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -50.0% | $1.24 | $1.41 | +13.71% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -250.1% | $1.04 | $0.93 | -10.58% |
Q2 FY2026+1.05%
Report Date
May 13, 2026
EPS Beat/Miss
+2300.0%
Price Before
$1.91
Price After
$1.93
Q1 FY2026-20.79%
Report Date
Mar 18, 2026
EPS Beat/Miss
-800.0%
Price Before
$2.79
Price After
$2.21
Q4 FY2025-9.81%
Report Date
Nov 13, 2025
EPS Beat/Miss
-50.0%
Price Before
$2.14
Price After
$1.93
Q3 FY2025-5.59%
Report Date
Aug 14, 2025
EPS Beat/Miss
-93.3%
Price Before
$1.61
Price After
$1.52
Q2 FY2025-40.48%
Report Date
May 9, 2025
EPS Beat/Miss
-162.5%
Price Before
$2.89
Price After
$1.72
Q1 FY2025+9.37%
Report Date
Mar 17, 2025
EPS Beat/Miss
+28.6%
Price Before
$2.24
Price After
$2.45
Q4 FY2024+13.71%
Report Date
Nov 14, 2024
EPS Beat/Miss
-50.0%
Price Before
$1.24
Price After
$1.41
Q3 FY2024-10.58%
Report Date
Aug 14, 2024
EPS Beat/Miss
-250.1%
Price Before
$1.04
Price After
$0.93
Avg Beat Reaction+5.21%
Avg Miss Reaction-12.26%
Beat Rate2 / 8 quarters
Largest Move-40.48% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PLX ends December
Protalix BioTherapeutics, Inc. (PLX) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $0.22 — beating the analyst consensus of $-0.01 by +2300.0%. The next PLX earnings date is expected around September 1, 2026.
Each quarter, investors track PLX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PLX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PLX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PLX earnings · 5 questionsProtalix BioTherapeutics, Inc.'s next earnings report is expected around September 1, 2026. PLX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PLX historically reports after market close (AMC).
PLX earnings datewhen is PLX earningsPLX next earnings datewhen does PLX report earningsPLX earnings calendar
▸ Source: FMP · Protalix BioTherapeutics, Inc. SEC filings · US GAAP · Protalix BioTherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026